Animal diseases remain a major constraint to livestock productivity and public health, necessitating accurate, early diagnostic methods. This review examines the classification and mechanisms of diagnostic, prognostic, and predictive biomarkers in veterinary medicine and evaluates how advanced technologies enable their discovery. Mechanistically, biomarkers function as molecular indicators of disease presence, progression, or therapeutic response, and are essential in species where clinical signs often appear late or are non-specific. We detail the contribution of high-throughput omics platforms, genomics (NGS, RNA-Seq), proteomics (LC-MS/MS, DIGE), and metabolomics (NMR, LC-MS/MS) in identifying disease-specific molecular signatures. Emerging technologies, including CRISPR/Cas9, AI-enhanced imaging, aptamer-based biosensors, and microfluidic devices, show significant diagnostic potential. Case studies, including canine melanoma, bovine respiratory disease complex (BRDC), and congenital portosystemic shunts in dogs, illustrate the real-world applicability of biomarkers. Challenges such as a lack of standardization, species variability, and poor clinical translation are acknowledged. The review concludes that integrating biomarker mechanisms with advanced analytical technologies is key to advancing veterinary diagnostics and disease control.

Sulforaphane (SFN), a bioactive compound sourced from cruciferous vegetables, offers significant antioxidant and anti-inflammatory benefits yet, its stability in animal feed is a challenge. Nanotechnology-based encapsulation, specifically ionic gelation, has demonstrated efficacy in improving the stability and bioavailability of SFN. This review examines the application of natural polymers such as chitosan and alginate in ionic gelation for the encapsulation of SFN. It also discusses how these polymers can prevent SFN from degrading while traversing the digestive tract. Encapsulated SFN has shown enhanced nutritional absorption, elevated immune responses, and reduced oxidative stress in animals. However, challenges persist in identifying optimal methods for encapsulating various species, including enhancing encapsulation effectiveness, particle size, and controlled release mechanisms. Additionally, regulatory concerns regarding the safety and environmental impacts of nanoparticles in feed must be addressed. Future research should focus on improving encapsulation techniques and ensuring the safe application of SFN-loaded nanocarriers in livestock feed.

Cancer therapy is increasingly shaped by the need for agents that are both mechanistically precise and clinically tolerable. Sulforaphane (SFN), a dietary isothiocyanate enriched in cabbage-family vegetables such as cauliflower and Brussels sprouts, has emerged as a pleiotropic modulator of tumor biology. This review synthesizes current evidence that SFN regulates diverse cancer-relevant processes, including redox homeostasis, cell-cycle progression, apoptosis, autophagy and epigenetic remodeling, largely through coordinated effects on transcriptional (for example, Nrf2, MAPK, NF-κB and AP-1), post-transcriptional (microRNAs and messenger RNAs) and epigenetic (DNA methyltransferases and histone deacetylases) networks. We then examine how functional nucleic acids, including aptamers, small interfering RNAs, microRNAs and tetrahedral DNA nanostructures, can be engineered to guide SFN to tumor cells, amplify pathway-specific effects and overcome resistance. Particular emphasis is placed on nanotechnology-enabled delivery platforms that enhance SFN stability, bioavailability and tumor selectivity. Finally, we outline key challenges, such as context-dependent Nrf2 activity, inter-individual variability in metabolism and incomplete clinical validation, and propose priorities for translating SFN-based functional nucleic acid systems into rational, combination-ready strategies for precision oncology.

Aflatoxin B1 (AFB1) is a highly toxic mycotoxin which can be carried over into animal products and cause deterioration of livestock productivity when fed to livestock and wildlife. This review proposes a biomarker-guided framework for improving the early assessment of AFB1 exposure and toxicological responses in animal models. Oral exposure leads to the absorption of AFB1, which is bioactivated in the liver to the reactive AFB1-exo-8,9-epoxide that causes DNA and protein adduct formation, inflammation, mitochondrial apoptosis, and other effects. Cytochrome P450 activation and glutathione-dependent detoxification are in balance in determining susceptibility species, and this balance is different for poultry, pigs, ruminants, and rodents. In addition to traditional liver enzymes and histopathology, we highlight mechanistically informative biomarkers such as metabolites of aflatoxin, DNA and albumin adduct, lipid peroxidation products, antioxidant indices, cytokines, apoptotic markers, as well as signals involved in the Nrf2/NFκB pathway. AFB1 also damages the integrity of the intestinal barrier, the maintenance of the intestinal gut microbiota, reproductive function, growth performance, and development, thus creating a gut–liver-systemic toxic cascade. Finally, an assessment of stage-targeted interventions such as aluminosilicate binders, adsorbents derived from yeast, probiotics and nano-enabled interventions is conducted as viable tools for the reduction in exposure and injury. This review offers targeted mitigation strategies for early diagnosis of aflatoxicosis in animal production systems based on a biomarker approach.

Sulforaphane (SFN), a bioactive compound sourced from cruciferous vegetables, offers significant antioxidant and anti-inflammatory benefits yet its stability in animal feed is a challenge. Nanotechnology-based encapsulation, specifically ionic gelation, has demonstrated efficacy in improving the stability and bioavailability of SFN. This review examines the application of natural polymers such as chitosan and alginate in ionic gelation for the encapsulation of SFN. It also discusses how these polymers can prevent SFN from degrading while traversing the digestive tract. Encapsulation strategies for SFN have been associated with improved bioavailability, with absorption reported in experimental modules, to modulate immune-related and oxidative-stress pathways. However, challenges persist in identifying optimal methods for encapsulating various species, including enhancing encapsulation effectiveness, particle size, and controlled release mechanisms. Additionally, regulatory concerns regarding the safety and environmental impacts of nanoparticles in feed must be addressed. Future research should focus on improving encapsulation techniques and ensuring the safe application of SFN-loaded nanocarriers in livestock feed.